Enzalutamide leads to 40% lower risk of death in prostate cancer
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
First-of-its-kind active cosmetic ingredient directly activates the oxytocin receptor, mimicking the dermatological effects of being in love
Subscribe To Our Newsletter & Stay Updated